Orion Group Holdings Announces Board Retirements and Size Reduction

Myriad Genetics' MyChoice CDx Test has received FDA approval as the companion diagnostic for Zejula (niraparib) in ovarian cancer. The test determines homologous recombination deficiency (HRD) status and is used to stratify patients for treatment with Zejula. The test identifies nearly 50% of patients with advanced ovarian cancer who have HRD-positive tumors, making treatment decisions more personalized.